The Benefits of Clustering in TNF Receptor Superfamily Signaling

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Sep 4

PMID 37662920

Authors

Eva S Vanamee

Denise L Faustman

Affiliations

Soon will be listed here.

Abstract

The tumor necrosis factor (TNF) receptor superfamily is a structurally and functionally related group of cell surface receptors that play crucial roles in various cellular processes, including apoptosis, cell survival, and immune regulation. This review paper synthesizes key findings from recent studies, highlighting the importance of clustering in TNF receptor superfamily signaling. We discuss the underlying molecular mechanisms of signaling, the functional consequences of receptor clustering, and potential therapeutic implications of targeting surface structures of receptor complexes.

Citing Articles

CD163, a novel receptor for TNF, was revealed by proximity ligation assay.

Cousin A, Oger M, de Jenlis A, Lejart A, Barbier L, Riccobono D Heliyon. 2025; 11(3):e42194.

PMID: 39995928 PMC: 11848091. DOI: 10.1016/j.heliyon.2025.e42194.

Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule.

Akiba H, Ise T, Satoh R, Abe Y, Tsumoto K, Ohno H Antib Ther. 2025; 8(1):56-67.

PMID: 39958564 PMC: 11826918. DOI: 10.1093/abt/tbaf002.

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N Front Immunol. 2025; 15:1473815.

PMID: 39867912 PMC: 11757143. DOI: 10.3389/fimmu.2024.1473815.

Turn TRAIL Into Better Anticancer Therapeutic Through TRAIL Fusion Proteins.

Wang Y, Qian X, Wang Y, Yu C, Feng L, Zheng X Cancer Med. 2024; 14(1):e70517.

PMID: 39740038 PMC: 11683677. DOI: 10.1002/cam4.70517.

Apoptotic signaling by TNFR1 is inhibited by the α2-6 sialylation, but not α2-3 sialylation, of the TNFR1 N-glycans.

Hwang J, Rao T, Tao J, Sha B, Narimatsu Y, Clausen H J Biol Chem. 2024; 301(1):108043.

PMID: 39615678 PMC: 11732462. DOI: 10.1016/j.jbc.2024.108043.

References

Legler K, Hauser C, Egberts J, Willms A, Heneweer C, Boretius S . The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis. 2018; 9(5):445. PMC: 5906476. DOI: 10.1038/s41419-018-0478-0. View

Barclay A . Membrane proteins with immunoglobulin-like domains--a master superfamily of interaction molecules. Semin Immunol. 2003; 15(4):215-23. DOI: 10.1016/s1044-5323(03)00047-2. View

Siegel R, Frederiksen J, Zacharias D, Chan F, Johnson M, Lynch D . Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 2000; 288(5475):2354-7. DOI: 10.1126/science.288.5475.2354. View

Vanamee E, Faustman D . Structural principles of tumor necrosis factor superfamily signaling. Sci Signal. 2018; 11(511). DOI: 10.1126/scisignal.aao4910. View

Zapata J, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I . CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. Front Immunol. 2018; 9:2618. PMC: 6262405. DOI: 10.3389/fimmu.2018.02618. View

Siegel R, Muppidi J, Sarker M, Lobito A, Jen M, Martin D . SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol. 2004; 167(4):735-44. PMC: 2172594. DOI: 10.1083/jcb.200406101. View

Scott F, Stec B, Pop C, Dobaczewska M, Lee J, Monosov E . The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature. 2009; 457(7232):1019-22. PMC: 2661029. DOI: 10.1038/nature07606. View

Yu X, Orr C, Chan H, James S, Penfold C, Kim J . Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 2023; 614(7948):539-547. DOI: 10.1038/s41586-022-05673-2. View

Yang W, Alvarado A, Glatter T, Ringgaard S, Briegel A . Baseplate variability of chemoreceptor arrays. Proc Natl Acad Sci U S A. 2018; 115(52):13365-13370. PMC: 6310817. DOI: 10.1073/pnas.1811931115. View

10.

Yin Q, Lin S, Lamothe B, Lu M, Lo Y, Hura G . E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol. 2009; 16(6):658-66. PMC: 2834951. DOI: 10.1038/nsmb.1605. View

11.

Vanamee E, Faustman D . On the TRAIL of Better Therapies: Understanding TNFRSF Structure-Function. Cells. 2020; 9(3). PMC: 7140660. DOI: 10.3390/cells9030764. View

12.

Sherman E, Barr V, Samelson L . Super-resolution characterization of TCR-dependent signaling clusters. Immunol Rev. 2013; 251(1):21-35. PMC: 3539238. DOI: 10.1111/imr.12010. View

13.

Roux K, Strelets L, Michaelsen T . Flexibility of human IgG subclasses. J Immunol. 1997; 159(7):3372-82. View

14.

Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit G, Pfizenmaier K . Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009; 183(3):1851-61. DOI: 10.4049/jimmunol.0802597. View

15.

Argiriadi M, Benatuil L, Dubrovska I, Egan D, Gao L, Greischar A . CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019; 20(1):29. PMC: 6683420. DOI: 10.1186/s12860-019-0213-4. View

16.

Samson A, Garnish S, Hildebrand J, Murphy J . Location, location, location: A compartmentalized view of TNF-induced necroptotic signaling. Sci Signal. 2021; 14(668). DOI: 10.1126/scisignal.abc6178. View

17.

Graves J, Kordich J, Huang T, Piasecki J, Bush T, Sullivan T . Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell. 2014; 26(2):177-89. DOI: 10.1016/j.ccr.2014.04.028. View

18.

Orr C, Fisher H, Yu X, Chan C, Gao Y, Duriez P . Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci Immunol. 2022; 7(73):eabm3723. DOI: 10.1126/sciimmunol.abm3723. View

19.

Leyland R, Watkins A, Mulgrew K, Holoweckyj N, Bamber L, Tigue N . A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. Clin Cancer Res. 2017; 23(13):3416-3427. DOI: 10.1158/1078-0432.CCR-16-2000. View

20.

Li M, Hazelbauer G . Selective allosteric coupling in core chemotaxis signaling complexes. Proc Natl Acad Sci U S A. 2014; 111(45):15940-5. PMC: 4234562. DOI: 10.1073/pnas.1415184111. View